A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19

A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19

Abstract An inhibitor of plasminogen activator inhibitor (PAI)-1, TM5614, inhibited thrombosis, inflammation, and fibrosis in several experimental mouse models. To evaluate the efficacy and safety of TM5614 in human COVID-19 pneumonia, phase IIa and IIb trials were conducted. In an open-label, singl...

Full description

Bibliographic Details
Main Authors: Toyohiro Hirai, Koichiro Asano, Isao Ito, Yasunari Miyazaki, Hisatoshi Sugiura, Mehmet Agirbasli, Seiichi Kobayashi, Makoto Kobayashi, Daishi Shimada, Ichiro Natsume, Tsutomu Kawasaki, Takehiko Ohba, Sakurako Tajiri, Fumio Sakamaki, Masamichi Mineshita, Takahisa Takihara, Kiyoshi Sekiya, Keisuke Tomii, Hiromi Tomioka, Hideo Kita, Yasuo Nishizaka, Motonari Fukui, Toshio Miyata, Hideo Harigae
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-50445-1

Internet

https://doi.org/10.1038/s41598-023-50445-1

Similar Items